The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-life Clinical Data
DOI:
https://doi.org/10.2340/00015555-3642Keywords:
cutaneous T cell lymphoma, mycosis fungoides, biologic treatment, anti-TNF?, anti-IL-12/23, anti-IL23, anti-IL17AAbstract
Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were treated with biologics; 12 for inflammatory conditions coexisting with MF, and 7 for MF misdiagnosed as an inflammatory skin disease. Eight patients were treated with anti-tumour necrosis factor-?-monotherapy; 6 had early-stage MF, in 3 patients MF preceded and in 3 MF was diagnosed after initiation of biologics, with no stage-progression or with stable disease, respectively (median treatment time concurrent with MF 57 months). Two patients had advanced stage MF: IIB, treated for 15 months with no stage-progression, and IVA1, treated for 8 months, died of disease 10 months later. The other 11/19 patients received anti-interleukin-17A and/or anti-interleukin-12/23 or anti-interleukin-23 (with/without anti-tumour necrosis factor-?/anti-interleukin-4/13), with stage-progression in 8 patients after a median of 8 months? treatment. Although, in general, biologics should be avoided in patients with MF, these results indicate that anti-tumour necrosis factor-?-monotherapy might not aggravate the disease course in early-stage patients. Interleukin-17A, interleukin-12/23 and interleukin-23 pathway-blockers may prompt progression of MF.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Iris Amitay-Laish, Emmanuella Guenova, Pablo L. Ortiz-Romero, Cristina Vico-Alonso, Sima Rozati, Larisa J. Geskin, Vasiliki Nikolaou, Evangelia Papadavid, Aviv Barzilai, Lev Pavlovsky, Elena Didkovsky, Hadas Prag Naveh, Oleg E. Akilov, Emmilia Hodak
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.